New and Effective Treatment of Experimentally Induced Venous Thrombosis with Anti-inflammatory rPSGL-Ig

SummaryP-selectin antagonism decreases thrombosis and inflammation in animal models of venous thrombosis (VT) prophylaxis. This study defines results using a P-selectin receptor antagonist for VT treatment.Eight juvenile baboons underwent 6 h of iliofemoral venous stasis to produce an occlusive VT. Two days later, animals were treated for 14 days with rPSGL-Ig, 4 mg/kg (n3), LMWH (n2) or saline (n3) and treatment continued weekly (rPSGL-Ig) or daily (LMWH, saline). The animals were examined and sacrificed 14 days after treatment initiation (n4) or on day 90 (n4).Percent spontaneous vein reopening revealed a significant increase (p <0.05) in the proximal iliac vein in rPSGL-Ig and LMWH animals compared to controls (62%, 70% vs 8%), without differences in inflammation. No anticoagulation, thrombocytopenia, or wound complications were found in rPSGL-Ig animals. At 90 days, recanalization with iliac vein valve competence was found in treated animals.rPSGLIg successfully treated established VT without anticoagulation.

Download Full-text

Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up

Case Reports in Rheumatology ◽

10.1155/2014/536856 ◽

2014 ◽

Vol 2014 ◽

pp. 1-5 ◽

Cited By ~ 1

Author(s):

Jácome Bruges-Armas ◽

Bruno F. Bettencourt ◽

Ana R. Couto ◽

Manuela Lima ◽

Ana M. Rodrigues ◽

...

Keyword(s):

Side Effects ◽

Receptor Antagonist ◽

Effective Treatment ◽

Diffuse Idiopathic Skeletal Hyperostosis ◽

Calcium Pyrophosphate ◽

Inflammatory Drugs ◽

Anti Inflammatory

Objectives. To investigate the efficacy of infliximab in the treatment of severe calcium pyrophosphate deposition diseases (CPPD).Methods. Two patients with severe CPPD and diffuse idiopathic skeletal hyperostosis- (DISH-) like phenotype are described. Both patients were resistant to therapy with nonsteroidal anti-inflammatory drugs (NSAIDs). Both patients were treated with infliximab, a TNF-αreceptor antagonist, for nine years.Results. Treatment with infliximab resulted in major clinical and laboratory improvements without relevant side effects.Conclusions. These results suggest that infliximab may be an effective treatment of severe CPDD.

Download Full-text

ANTI-INFLAMMATORY ACTIVITY OF H1 RECEPTOR ANTAGONIST CETIRIZINE IN ANIMAL MODELS

Journal of Evolution of Medical and Dental Sciences ◽

10.14260/jemds/499 ◽

2013 ◽

Vol 2 (13) ◽

pp. 2050-2059

Author(s):

Vardhamane S.H ◽

Jeevangi Santoshkumar

Keyword(s):

Animal Models ◽

Receptor Antagonist ◽

Inflammatory Activity ◽

H1 Receptor ◽

Anti Inflammatory ◽

H1 Receptor Antagonist

Download Full-text

Glucan particles as anti-inflammatory agent and drug delivery system for natural compounds in experimentally induced intestinal inflammation in vivo

10.1055/s-0037-1608375 ◽

2017 ◽

Author(s):

D Rotrekl ◽

Z Vochyánová ◽

L Paráková ◽

I Saloň ◽

P Šalamúnová ◽

...

Keyword(s):

Drug Delivery ◽

Drug Delivery System ◽

Delivery System ◽

Intestinal Inflammation ◽

Natural Compounds ◽

Inflammatory Agent ◽

Anti Inflammatory ◽

Experimentally Induced

Download Full-text

Consideration of a Pharmacological Combinatorial Approach to Inhibit Chronic Inflammation in Alzheimer’s Disease

Current Alzheimer Research ◽

10.2174/1567205016666191106095038 ◽

2019 ◽

Vol 16 (11) ◽

pp. 1007-1017 ◽

Cited By ~ 1

Author(s):

James G. McLarnon

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Animal Models ◽

Chronic Inflammation ◽

Preventive Strategy ◽

Subsequent Work ◽

Activated Microglia ◽

Starting Point ◽

Anti Inflammatory ◽

Cocktail Approach

A combinatorial cocktail approach is suggested as a rationale intervention to attenuate chronic inflammation and confer neuroprotection in Alzheimer’s disease (AD). The requirement for an assemblage of pharmacological compounds follows from the host of pro-inflammatory pathways and mechanisms present in activated microglia in the disease process. This article suggests a starting point using four compounds which present some differential in anti-inflammatory targets and actions but a commonality in showing a finite permeability through Blood-brain Barrier (BBB). A basis for firstchoice compounds demonstrated neuroprotection in animal models (thalidomide and minocycline), clinical trial data showing some slowing in the progression of pathology in AD brain (ibuprofen) and indirect evidence for putative efficacy in blocking oxidative damage and chemotactic response mediated by activated microglia (dapsone). It is emphasized that a number of candidate compounds, other than ones suggested here, could be considered as components of the cocktail approach and would be expected to be examined in subsequent work. In this case, systematic testing in AD animal models is required to rigorously examine the efficacy of first-choice compounds and replace ones showing weaker effects. This protocol represents a practical approach to optimize the reduction of microglial-mediated chronic inflammation in AD pathology. Subsequent work would incorporate the anti-inflammatory cocktail delivery as an adjunctive treatment with ones independent of inflammation as an overall preventive strategy to slow the progression of AD.

Download Full-text